<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 20, 1996
ROBERTS PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
(exact name of registrant as specified in its charter)
NEW JERSEY 1-1-432 22-2429994
- ------------------- ----------------- -----------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 908-389-1182
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Former name or former address, if changed from last report)
<PAGE>
- 2 -
Item 5. Other Events
------------
Roberts Pharmaceutical Corporation announced it has filed the
first several process patents with the U.S. Patent and Trademark Office for
improved methods for the chemical synthesis of anagrelide, the active ingredient
in AGRELIN(R). AGRELIN is a anti-platelet drug whose New Drug Application is
currently under active regulatory review by the Food and Drug Administration.
The Company also announced that this patent application was also
submitted to international markets including Europe, Scandinavia, and Japan.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ROBERTS PHARMACEUTICAL CORPORATION
----------------------------------
(Registrant)
Date: March 21, 1996 By: /s/ Anthony A. Rascio
-------------------------------
Anthony A. Rascio
Vice President
